Literature DB >> 25014586

Successful management of angiolymphoid hyperplasia with eosinophilia in a split-face trial of topical tacrolimus and timolol solution.

Anna Chacon1, Jessica Mercer.   

Abstract

Angiolymphoid hyperplasia with eosinophilia (ALHE) is an uncommon, benign condition characterized by multiple benign angiomatous nodules or plaques. Cutaneous lesions can be painful, pruritic, pulsatile, or potentially disfiguring resulting in significant morbidity. ALHE is a pathologic diagnosis featuring proliferations of capillary-sized vessels with epithelioid endothelial cells surrounded by larger, thick-walled vessels and accompanying eosinophils and lymphocytes. Surgery is generally required, however the skin lesions often recur after excision. ALHE is notoriously difficult to treat and many physicians would prefer a non-invasive treatment of choice. We report a case of ALHE that was successfully treated with the novel use of topical tacrolimus in a split-face trial with topical timolol solution.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25014586

Source DB:  PubMed          Journal:  G Ital Dermatol Venereol        ISSN: 0392-0488            Impact factor:   2.011


  3 in total

1.  Angiolymphoid Hyperplasia with Oeosinophilia Showing Promising Result with Intralesional Radio-frequency Ablation Therapy: A New Cost-effective and Hassle-free Modality of Treatment.

Authors:  Chintaginjala Aruna; Senthil Kumar Alagappan; Ramamurthy Damaraju Venkata Satya Bhaskara; Sruthi Kondaveeti
Journal:  J Cutan Aesthet Surg       Date:  2016 Oct-Dec

2.  Angiolymphoid Hyperplasia with Eosinophilia and its Response to the Combination of Radiofrequency Ablation and Topical Timolol.

Authors:  Pooja Arora; Neha Meena; Prafulla K Sharma; Minakshi Bhardwaj
Journal:  Indian Dermatol Online J       Date:  2017 Jul-Aug

3.  Angiolymphoid hyperplasia with eosinophilia: a case report.

Authors:  Alexey Youssef; Ali Ramez Hasan; Youssef Youssef; Lina Al-Soufi; Yahya Elshimali; Zuheir Alshehabi
Journal:  J Med Case Rep       Date:  2018-04-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.